REG - Cizzle Biotechnology - Result of AGM

Cizzle Biotechnology HoldingsAnnouncement

28/06/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb2600Ea&default-theme=true

RNS Number : 2600E  Cizzle Biotechnology Holdings PLC  28 June 2023

28 June 2023

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at
the Annual General Meeting ("AGM") of the Company held earlier today, all
resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

 Resolution                                                                     For                 Against            Votes withheld
                                                                                Total votes  %      Total votes  %
 1.   To receive the Company's annual report and accounts for the year ended    89,757,080   97.11  2,672,935    2.89  1,661,693
 31 December 2022
 2.    To approve the Directors' Remuneration Report                                         96.10  3,602,447    3.90  1,661,693

                                                                                88,827,568

 3.   To re-appoint Allan John Syms as a Director of the Company                             96.14               3.86  1,695,893

                                                                                88,827,578          3,568,237

 4.    To re-appoint PKF Littlejohn LLP as auditor of the Company               88,861,778   96.14  3,568,237    3.86

                                                                                                                       1,661,693

 5.    To authorise the Directors to determine the auditor's remuneration       88,861,778   96.14  3,568,237    3.86

                                                                                                                       1,661,693

 6.    Authorises the Directors to allot shares in the Company or to grant      88,661,778   95.92  3,768,237    4.08  1,661,693
 rights to subscribe for, or to convert any security into, shares in the
 Company
 7.    Authorise the Directors to allot equity securities disapplying           88,823,568   96.10  3,606,437    3.90  1,661,703
 pre-emption rights
 8.    That General Meetings may be called on not less than 14 days' notice     88,861,778   96.14  3,568,237    3.86  1,661,693

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com/)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEUFSAEDSEIM